Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrronium bromide (CHF 5259 pMDI) in uncontrolled asthma
2014-001442-16Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing CHF 5259 pMDI (glycopyrronium bromide) with Placebo pMDI (2 arms). Primary endpoint: FEV1 AUC0–12h normalized by time on Day 42. Started Aug 2014; status: completed.
02
Drugs
glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on 2014-001442-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001442-16.